SEE NEW EXPERT VIDEO SERIES ON MANAGING BIOBURDEN

PuraPly AM. Right from the start. For control all week long.

Get wounds moving as early as day 1 with the power of plus—native cross-linked ECM + broad-spectrum PHMB antimicrobial—backed by multiple real-world effectiveness studies and scientific evidence.1-7

ECM=extracellular matrix; PHMB=polyhexamethylene biguanide

REAL-WORLD STUDY: PURAPLY AM SUPPORTED HEALING IN LARGE, DIFFICULT-TO-HEAL WOUNDS

The first prospective, large (N=307), multicenter (28 sites) cohort study of PuraPly AM showed that 86% of all PuraPly AM-treated wounds demonstrated improvement in the wound bed condition.1

WATCH A VIDEO SUMMARY OR SEE ALL OF THE DATA FROM THE RESPOND REAL-WORLD EFFECTIVENESS STUDY 
The opening frame from the RESPOND: Real-World Effectiveness Study of PuraPly AM on Wounds video

Learn how PuraPly AM addresses key barriers to healing.

SEE NEW MECHANISM OF ACTION VIDEO FOR PURAPLY AM

SEE VIDEO 

TAKE CONTROL BEFORE BIOFILM RE-FORMS. USE PURAPLY AM AS EARLY AS DAY 1.*

Bioburden management with PuraPly AM following sharp debridement helps you move wounds out of the inflammatory phase.

WHY PURAPLY AM 

*Certain local coverage determinations may not allow skin substitute use until after conventional care at week 4.

PuraPly AM product shot

READY TO TAKE CONTROL OF 
THE HEALING ENVIRONMENT?

Talk to an Organogenesis Tissue Regeneration Specialist about the advanced antimicrobial barrier with native, cross-linked ECM + broad-spectrum PHMB.

Contact us

CONFIRMATION
OF CONTROL

Examine the scientific and real-world studies that demonstrate the effectiveness of PuraPly AM.

SCIENTIFIC EVIDENCE 
REAL-WORLD EVIDENCE 
Components that make up the Organogenesis Circle of Care program

Organogenesis' Circle of Care is a comprehensive program that provides the highest-quality customer service and reimbursement support. Our wide range of expertise includes:

VIEW ALL SERVICES 

Please refer to the PuraPly AM Instructions for Use for complete prescribing information.

REFERENCES:

  1. Bain MA, et al. J Comp Eff Res. 2020;9(10):691-703. doi:10.2217/cer-2020-0058
  2. Koullias GJ. Wounds. 2021;33(1):20-27.
  3. Hübner NO, et al. Skin Pharmacol Physiol. 2010;23(1 suppl):17-27.
  4. Oropallo AR. Plast Reconstr Surg Glob Open. 2019;7(1):e2047.
  5. Lintzeris D, et al. Wounds. 2018;30(3):72-78.
  6. Data on file. PDR-0001. Organogenesis Inc.
  7. Davis SC, et al. Int Wound J. 2021. Epub ahead of print. doi:10.1111/iwj.13600